Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: A method includes receiving, by a storage driver associated with a storage controller and a corresponding storage array, a data structure associated with an I/O request from a host, wherein the data structure is indicative of a virtual address. A top layer and a RAID core layer of a RAID miniport driver execute asynchronously to perform preprocessing operations including generating a linked plurality of physical I/O (PIO) data structures in accordance with the virtual address and a RAID configuration of the storage array, and storing a pointer to the linked plurality of PIO data structures. A protocol layer of the RAID miniport driver may then be executed synchronously to transfer, in accordance with the linked plurality of PIO data structures, I/O data corresponding to the I/O request between the storage controller and the storage array. Interrupt operations may then be performed synchronously to indicate completion of the I/O request to the host.

Abstract: An information handling system includes a first storage controller coupled to a first storage device, a second storage controller coupled to a second storage device where the first storage device and the second storage device comprise a virtual disk and a processor to initiate a first discovery of the first storage device, initiate a first discovery of the virtual disk on the first storage controller, complete the discovery of the first storage device, initiate a first discovery of the second storage device, initiate a second discovery of the virtual disk on the second storage controller, determine that a first timeout for the first discovery of the virtual disk on the first storage controller will expire prior to completing the first discovery of the second storage device, and initiate a second discovery of the first storage device in response to determining that the timeout will expire.

Abstract: A method includes receiving, by a storage driver associated with a storage controller and a corresponding storage array, a data structure associated with an I/O request from a host, wherein the data structure is indicative of a virtual address. A top layer and a RAID core layer of a RAID miniport driver execute asynchronously to perform pre-processing operations including generating a linked plurality of physical I/O (PIO) data structures in accordance with the virtual address and a RAID configuration of the storage array, and storing a pointer to the linked plurality of PIO data structures. A protocol layer of the RAID miniport driver may then be executed synchronously to transfer, in accordance with the linked plurality of PIO data structures, I/O data corresponding to the I/O request between the storage controller and the storage array. Interrupt operations may then be performed synchronously to indicate completion of the I/O request to the host.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: An information handling system recognizes PCIe-based RAID volumes, including RAID virtual disks spanning two or more NVMe storage drives, while performing boot, hibernation, and crash-dump functions, rather than treating each storage device and its corresponding storage controller separately. The information handling system may perform a two-tiered discovery/initialization process during which a storage protocol function driver detects and initializes physical storage controllers, a storage controller bus driver virtualizes all physical storage controllers of a particular storage protocol and exposes a single virtualized storage controller for the protocol. A virtual miniport driver may then detect RAID volumes associated with the virtual storage controller and initialize the detected RAID stack(s).

Abstract: A domain name registrar may create a customizable universal purchase path for all customers purchasing a given product. The registrar may create and store modular cross sell components that each has material for at least one product offered for sale by the registrar. Thereafter, the registrar may receive a request for a product from a customer. The registrar may determine a probability the customer will complete the purchase if shown upgrades and/or additional products. If the probability is low (or lower than a predefined threshold) the registrar may complete the purchase before displaying additional upgrades and/or additional products to the customer. This will maximize the conversion rate. Alternatively, if the probability is high (or higher than a predefined threshold) the registrar may create final page markups using the modular cross sell components and collected content and display the final page markups to the customer before completing the purchase with the customer.

Abstract: A domain name registrar may create a customizable universal purchase path for all customers purchasing a given product. The registrar may create and store modular cross sell components that each has material for at least one product offered for sale by the registrar. Thereafter, the registrar may receive a request for a product from a customer. The registrar may determine a probability the customer will complete the purchase if shown upgrades and/or additional products. If the probability is low (or lower than a predefined threshold) the registrar may complete the purchase before displaying additional upgrades and/or additional products to the customer. This will maximize the conversion rate. Alternatively, if the probability is high (or higher than a predefined threshold) the registrar may create final page markups using the modular cross sell components and collected content and display the final page markups to the customer before completing the purchase with the customer.

Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.

Abstract: An information handling system recognizes PCIe-based RAID volumes, including RAID virtual disks spanning two or more NVMe storage drives, while performing boot, hibernation, and crash-dump functions, rather than treating each storage device and its corresponding storage controller separately. The information handling system may perform a two-tiered discovery/initialization process during which a storage protocol function driver detects and initializes physical storage controllers, a storage controller bus driver virtualizes all physical storage controllers of a particular storage protocol and exposes a single virtualized storage controller for the protocol. A virtual miniport driver may then detect RAID volumes associated with the virtual storage controller and initialize the detected RAID stack(s).

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: A datacenter management server includes a datacenter operations manager and a datacenter infrastructure manager with an infrastructure viewer and an asset deployment tool. The datacenter operations manager compiles datacenter hierarchy information for a datacenter, including identity information for a virtualized environment and identity information for a virtualization capable system. The virtualization capable system is deployed as a stand-alone system of the datacenter. The datacenter infrastructure manager receives the datacenter hierarchy information, directs the infrastructure viewer to display a hierarchical overview of the datacenter, including depictions of the virtualized environment and the virtualization capable system. The hierarchical overview is based on the identity information. The datacenter infrastructure manager also receives a selection of the depictions from a user and directs the asset deployment tool to deploy the virtualization capable system to the virtualized environment.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: An information handling system (IHS) troubleshooting system includes a customer IHS including a plurality of components. A customer management system in the customer IHS detects a failure in a managed system and, in response, immediately triggers a device snapshot of the customer IHS. At least one managed system in the customer IHS includes a device snapshot engine that, in response to the customer management system triggering the device snapshot of the customer IHS, immediately create the device snapshot of the customer IHS. A device snapshot storage in the customer IHS stores the device snapshot of the customer IHS. A snapshot communication engine in the customer IHS sends the device snapshot of the customer IHS over the network to a support IHS. The support IHS may load the device snapshot into a virtual IHS and manage the virtual IHS to replicate the failure detected in the managed system for troubleshooting.

Abstract: Provided are methods for reducing intraocular pressure in the eye of a subject by administering neutral active soluble active hyaluronidase glycoproteins (sHASEGPs) and modified forms thereof to the eye. The sHASEGPs are soluble forms of human PH20 hyaluronidase. Also provided are the sHASEGPs, methods of manufacture, and uses thereof. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described. The sHASEGPs include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.

Abstract: A datacenter management server includes a datacenter operations manager and a datacenter infrastructure manager with an infrastructure viewer and an asset deployment tool. The datacenter operations manager compiles datacenter hierarchy information for a datacenter, including identity information for a virtualized environment and identity information for a virtualization capable system. The virtualization capable system is deployed as a stand-alone system of the datacenter. The datacenter infrastructure manager receives the datacenter hierarchy information, directs the infrastructure viewer to display a hierarchical overview of the datacenter, including depictions of the virtualized environment and the virtualization capable system. The hierarchical overview is based on the identity information. The datacenter infrastructure manager also receives a selection of the depictions from a user and directs the asset deployment tool to deploy the virtualization capable system to the virtualized environment.

Abstract: A datacenter management server includes a datacenter operations manager and a datacenter infrastructure manager with an infrastructure viewer and an asset deployment tool. The datacenter operations manager compiles datacenter hierarchy information for a datacenter, including identity information for a virtualized environment and identity information for a virtualization capable system. The virtualization capable system is deployed as a stand-alone system of the datacenter. The datacenter infrastructure manager receives the datacenter hierarchy information, directs the infrastructure viewer to display a hierarchical overview of the datacenter, including depictions of the virtualized environment and the virtualization capable system. The hierarchical overview is based on the identity information. The datacenter infrastructure manager also receives a selection of the depictions from a user and directs the asset deployment tool to deploy the virtualization capable system to the virtualized environment.

Abstract: An information handling system includes a first storage controller coupled to a first storage device, a second storage controller coupled to a second storage device where the first storage device and the second storage device comprise a virtual disk and a processor to initiate a first discovery of the first storage device, initiate a first discovery of the virtual disk on the first storage controller, complete the discovery of the first storage device, initiate a first discovery of the second storage device, initiate a second discovery of the virtual disk on the second storage controller, determine that a first timeout for the first discovery of the virtual disk on the first storage controller will expire prior to completing the first discovery of the second storage device, and initiate a second discovery of the first storage device in response to determining that the timeout will expire.